The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 05, 2015

Filed:

Sep. 09, 2013
Applicant:

Research Development Foundation, Carson City, NV (US);

Inventors:

Didier Trono, Vufflens-le-Chateau, CH;

Patrick Salmon, Arenthon, FR;

Assignee:

Research Development Foundation, Carson City, NV (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/071 (2010.01); C12N 15/86 (2006.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C07K 16/46 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61K 48/00 (2013.01); C12N 2740/16043 (2013.01); C12N 2740/16045 (2013.01); C12N 2800/108 (2013.01); C12N 2830/50 (2013.01); C12N 2840/20 (2013.01); C07K 14/55 (2013.01); C07K 14/70503 (2013.01); C07K 16/46 (2013.01);
Abstract

The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1 α promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.


Find Patent Forward Citations

Loading…